Pharmaceuticals, Biotechnology and Life Sciences
NOXXON said Wednesday it has enrolled the first patient in phase 1/2 trial in a therapy of increasing doses of…
Komen vows to drive breakthroughs for the most-deadly breast cancers and educate those who believe breast cancers are easily treated…
Annie Martin, Global Head of Presicion Medicine, has discussed the future of targeted therapy and genomic profiling, describing how to…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVEO Oncology (NASDAQ: AVEO) today announced that it has initiated enrollment in an open-label, multi-center Phase 1b/2 clinical…
– 22% Response Rate; 61% Disease Control Observed – REHOVOT, Israel & WILMINGTON, Del.–(BUSINESS WIRE)–Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical…
– First Presentation of Tucatinib With Trastuzumab in Metastatic Colorectal Cancer – – Findings Presented Today at the European Society…
– Phase I dose escalation continues; dosing is within the therapeutic range predicted by preclinical models – Early analysis of…
$46 Million Series A Round Co-led by ARCH Venture Partners and City Hill Ventures Company is Developing a Novel Class…
— The Company’s GPR174 Inhibitors Enhance Anti-Tumor Activities of Adenosine Pathway Inhibitors by up to 25-Fold — SEATTLE–(BUSINESS WIRE)–Omeros Corporation…
DUBLIN–(BUSINESS WIRE)–The “Opdivo” drug pipelines has been added to ResearchAndMarkets.com’s offering. Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) is a fully human…